Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

Abstract

Background Prevention, control, and treatment of respiratory tract cancers are important steps towards achieving target 3.4 of the UN Sustainable Development Goals (SDGs)-a one-third reduction in premature mortality due to non-communicable diseases by 2030. We aimed to provide global, regional, and national estimates of the burden of tracheal, bronchus, and lung cancer and larynx cancer and their attributable risks from 1990 to 2019.Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 methodology, we evaluated the incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) of respiratory tract cancers (ie, tracheal, bronchus, and lung cancer and larynx cancer). Deaths from tracheal, bronchus, and lung cancer and larynx cancer attributable to each risk factor were estimated on the basis of risk exposure, relative risks, and the theoretical minimum risk exposure level input from 204 countries and territories, stratified by sex and Socio-demographic Index (SDI). Trends were estimated from 1990 to 2019, with an emphasis on the 2010-19 period. Findings Globally, there were 2•26 million (95% uncertainty interval 2•07 to 2•45) new cases of tracheal, bronchus, and lung cancer, and 2•04 million (1•88 to 2•19) deaths and 45•9 million (42•3 to 49•3) DALYs due to tracheal, bronchus, and lung cancer in 2019. There were 209 000 (194 000 to 225 000) new cases of larynx cancer, and 123 000 (115 000 to 133 000) deaths and 3•26 million (3•03 to 3•51) DALYs due to larynx cancer globally in 2019. From 2010 to 2019, the number of new tracheal, bronchus, and lung cancer cases increased by 23•3% (12•9 to 33•6) globally and the number of larynx cancer cases increased by 24•7% (16•0 to 34•1) globally. Global age-standardised incidence rates of tracheal, bronchus, and lung cancer decreased by 7•4% (-16•8 to 1•6) and age-standardised incidence rates of larynx cancer decreased by 3•0% (-10•5 to 5•0) in males over the past decade; however, during the same period, agestandardised incidence rates in females increased by 0•9% (-8•2 to 10•2) for tracheal, bronchus, and lung cancer and decreased by 0•5% (-8•4 to 8•1) for larynx cancer. Furthermore, although age-standardised incidence and death rates declined in both sexes combined from 2010 to 2019 at the global level for tracheal, bronchus, lung and larynx cancers, some locations had rising rates, particularly those on the lower end of the SDI range. Smoking contributed to an estimated 64•2% (61•9-66•4) of all deaths from tracheal, bronchus, and lung cancer and 63•4% (56•3-69•3) of all deaths from larynx cancer in 2019. For males and for both sexes combined, smoking was the leading specific risk factor for age-standardised deaths from tracheal, bronchus, and lung cancer per 100 000 in all SDI quintiles and GBD regions in 2019. However, among females, household air pollution from solid fuels was the leading specific risk factor in the low SDI quintile and in three GBD regions (central, eastern, and wester...

Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study

“…In the present study, we evaluated the real-world population data of regional registries on a global scale, revealing the global patterns and trends in incidence and mortality of TBL cancer. We found that 1 a substantial number of countries with very high HDI had higher incidence and mortality ASRs in both men and women than other countries 2 ; decreasing trends in mortality were found in the males of almost all countries, whereas females of nearly half of the countries had an increasing trend in mortality 3 ; decreasing trends in incidence were found among males of the majority of countries, especially for men younger than 50 years old 4 ; females of most countries were identified to have an increasing trend in incidence, while females younger than 50 years exhibited a quite opposite trend.…”

“… 1 A recent study has revealed that smoking is still the primary risk factor for TBL cancer, and other risk factors include air pollution, exposure to asbestos and high fasting plasma glucose. 2 , 3 The survival rate of TBL cancer is relatively poor and it is still regarded as a substantial public health burden. 4 And early screening has a great potential for decreasing the mortality of tracheal, bronchus, and lung cancer.…”

“…Previous studies have demonstrated the incidence and mortality rate of TBL in different continents or groups of countries determined by their Socio-demographic Index, suggesting that TBL cancer is more prevalent among countries with higher Socio-demographic Index. 2 Another study has revealed the differences in incidence and death trends of TBL cancer in various specific regions. 7 Moreover, Sung et al.…”

Topological Abnormalities of Pallido-Thalamo-Cortical Circuit in Functional Brain Network of Patients With Nonchemotherapy With Non-small Cell Lung Cancer

“…Lung cancer is one of the most malignant cancers with high morbidity and mortality rate for both men and women in the world. Non-small cell lung cancer (NSCLC) is one subtype of lung cancer, which accounts for 85% of all the lung cancers (1). Although lung cancer has not been associated historically with abnormalities of the central neural system, an increasing body of evidence suggests that patients with lung cancer may be associated with neurocognitive impairments (2)(3)(4)(5).…”

Controlled supramolecular interaction to enhance the bioavailability of hesperetin to targeted cancer cells through graphyne: a comprehensive in silico study

“…Cancer is a deadly disease with more than 10 million new cases each year 1 due to low specificity, poor solubility, poor bioavailability, multi-drug resistance, low therapeutic results, and high cytotoxicity of conventional chemotherapeutic medication. 2 Prostate, lungs, 3 stomach, 4 and colorectal cancer 5 are different and the most common types of cancer.…”